CoChat

What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities

Open access
Strasburger, S. E., Bhimani, P. M., Kaabe, J. H., Krysiak, J. T., Nanchanatt, D. L., Nguyen, T. N., Pough, K. A., Prince, T. A., Ramsey, N. S., Savsani, K. H., Scandlen, L., Cavaretta, M. J., Raffa, R. B. · 2017 · Journal of Clinical Pharmacy and Therapeutics
Cited by 84

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

WHAT IS KNOWN AND OBJECTIVE: Abundant clinical data now confirm that ketamine produces a remarkable rapid-onset antidepressant effect - hours or days - in contrast to the delayed onset (typically weeks) of current antidepressant drugs. This surprising and revolutionary finding may lead to the development of life-saving pharmacotherapy for depressive illness by reducing the high suicide risk associated with the delayed onset of effect of current drugs. As ketamine has serious self-limiting drawbacks that restrict its widespread use for this purpose, a safer alternative is needed. Our objective is to review the proposed mechanism(s) of ketamine's rapid-onset antidepressant action for new insights into the physiological basis of depressive illness that may lead to new and novel targets for antidepressant drug discovery. METHODS: A search was conducted on published literature (e.g. PubMed) and Internet sources to identify information relevant to ketamine's rapid-acting antidepressant action and, specifically, to the possible mechanism(s) of this action. Key search words included 'ketamine', 'antidepressant', 'mechanism of action', 'depression' and 'rapid acting', either individually or in combination. Information was sought that would include less well-known, as well as well-known, basic pharmacologic properties of ketamine and that identified and evaluated the several hypotheses about ketamine's mechanism of antidepressant action. RESULTS: Whether the mechanistic explanation for ketamine's rapid-onset antidepressant action is related to its well-known antagonism of the NMDA (N-Methyl-d-aspartate) subtype of glutamate receptor or to something else has not yet been fully elucidated. The evidence from pharmacologic, medicinal chemistry, animal model and drug-discovery sources reveals a wide variety of postulated mechanisms. WHAT IS NEW AND CONCLUSION: The surprising discovery of ketamine's rapid-onset antidepressant effect is a game-changer for the understanding and treatment of depressive illness. There is some convergence on NMDA receptor antagonism as a likely, but to date unproven, common mechanism. The surprising number of other mechanisms, and the several novel biochemical aetiologies of depression proposed, suggests exciting new drug-discovery targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jcpt.12497

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 37

  1. American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders, 10.1176/appi.books.9780890425596 · DOI · Paper page
  2. Klein, 2013, Predictors of first lifetime onset of major depressive disorder in young adulthood, J Abnorm Psychol, 122, 1, 10.1037/a0029567 · DOI · Paper page
  3. Pasquini, 2014, Ethiopathogenesis of depressive disorders, Clin Pract Epidemiol Ment Health, 10, 166, 10.2174/1745017901410010166 · DOI
  4. O'Leary, 2015, Faster, better, stronger: towards new antidepressant therapeutic strategies, Eur J Pharmacol, 753, 32, 10.1016/j.ejphar.2014.07.046 · DOI
  5. Jarrett, 2008, How much cognitive therapy, for which patients, will prevent depressive relapse?, J Affect Disord, 111, 185, 10.1016/j.jad.2008.02.011 · DOI
  6. Segman, 1995, Onset and time course of antidepressant action: psychopharmacological implications of a controlled trial of electroconvulsive therapy, Psychopharmacology, 119, 440, 10.1007/BF02245860 · DOI
  7. Grözinger, 2015, On the significance of elektroconvulsive therapy in the treatment of severe mental diseases, Wien Klin Wochenschr, 127, 297, 10.1007/s00508-015-0749-z · DOI
  8. Drewniany, 2015, Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression, J Clin Pharm Ther, 40, 125, 10.1111/jcpt.12238 · DOI
  9. Dutta, 2015, Ketamine and other potential glutamate antidepressants, Psychia Res, 225, 1, 10.1016/j.psychres.2014.10.028 · DOI
  10. DeWilde, 2015, The promise of ketamine for treatment-resistant depression: current evidence and future directions, Ann N Y Acad Sci, 1345, 47, 10.1111/nyas.12646 · DOI · Paper page
  11. Preskorn, 2008, An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder, J Clin Psychopharmacol, 28, 631, 10.1097/JCP.0b013e31818a6cea · DOI · Paper page
  12. Lauterbach, 2011, Dextromethorphan as a potential rapid-acting antidepressant, Med Hypotheses, 76, 717, 10.1016/j.mehy.2011.02.003 · DOI
  13. Ates-Alagoz, 2013, NMDA receptor antagonists for treatment of depression, Pharmaceuticals (Basel), 6, 480, 10.3390/ph6040480 · DOI · Paper page
  14. Serafini, 2013, Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression, Curr Pharm Des, 19, 1898, 10.2174/13816128113199990293 · DOI · Paper page
  15. Pittenger, 2007, The NMDA receptor as a therapeutic target in major depressive disorder, CNS Neurol Disord Drug Targets, 6, 101, 10.2174/187152707780363267 · DOI · Paper page
  16. Zappettini, 2014, Nicotinic alpha7 receptor activation selectively potentiates the function of NMDA receptors in glutamatergic terminals of the nucleus accumbens, Front Cell Neurosci, 8, 332, 10.3389/fncel.2014.00332 · DOI
  17. Fernandes, 2015, Inhibition of in vivo [3H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice, Eur J Pharmacol, 766, 1, 10.1016/j.ejphar.2015.08.044 · DOI
  18. Yilmaz, 2011, Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model, J Membr Biol, 242, 145, 10.1007/s00232-011-9385-3 · DOI
  19. Taylor, 2008, Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy, J Psychopharmacol, 22, 473, 10.1177/0269881107081510 · DOI · Paper page
  20. Godlewska, 2014, Short-term escitalopram treatment and hippocampal volume, Psychopharmacology, 231, 4579, 10.1007/s00213-014-3771-3 · DOI
  21. Boyer, 1998, Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study, J Molec Neurosci, 10, 219, 10.1007/BF02761776 · DOI
  22. Nowak, 1998, Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors, Eur J Pharmacol, 342, 367, 10.1016/S0014-2999(97)01589-6 · DOI
  23. Muhonen, 2008, Treatment of alcohol dependence in patients with co-morbid major depressive disorder - predictors for the outcomes with memantine and escitalopram medication, Subst Abuse Treat Prev Policy, 3, 20, 10.1186/1747-597X-3-20 · DOI · Paper page
  24. Dietrich, 2000, Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial, Bipolar Disord, 2, 65, 10.1034/j.1399-5618.2000.020110.x · DOI · Paper page
  25. Stryjer, 2003, Amantadine as augmentation therapy in the management of treatment-resistant depression, Int Clin Psychopharmacol, 18, 93, 10.1097/00004850-200303000-00005 · DOI · Paper page
  26. Zarate, 2004, An open-label trial of riluzole in patients with treatment-resistant major depression, Am J Psychiatry, 161, 171, 10.1176/appi.ajp.161.1.171 · DOI · Paper page
  27. Sanacora, 2007, Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms, Biol Psychiatry, 61, 822, 10.1016/j.biopsych.2006.08.037 · DOI · Paper page
  28. Skolnick, 2015, Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test, Acta Neuropsychiatr, 27, 228, 10.1017/neu.2015.14 · DOI
  29. Preskorn, 2015, Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent, J Psychia Pract, 21, 140, 10.1097/01.pra.0000462606.17725.93 · DOI · Paper page
  30. Miller, 2013, Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression, Neuropsychopharmacology, 38, 1607, 10.1038/npp.2013.140 · DOI
  31. Russi, 1992, Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions, J Neurochem, 59, 2076, 10.1111/j.1471-4159.1992.tb10097.x · DOI · Paper page
  32. Stone, 2001, Kynurenines in the CNS: from endogenous obscurity to therapeutic importance, Prog Neurobiol, 64, 185, 10.1016/S0301-0082(00)00032-0 · DOI · Paper page
  33. Stone, 2002, Endogenous kynurenines as targets for drug discovery and development, Nat Rev Drug Discov, 1, 609, 10.1038/nrd870 · DOI · Paper page
  34. Connick, 1992, Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity, Gen Pharmacol, 23, 235, 10.1016/0306-3623(92)90017-E · DOI
  35. Yuhas, 2015, Immunomodulatory activity of ketamine in human astroglial A172 cells: possible relevance to its rapid antidepressant activity, J Neuroimmunol, 282, 33, 10.1016/j.jneuroim.2015.03.012 · DOI
  36. Mlyniec, 2015, Study of antidepressant drugs in GPR39 (zinc receptor(-)/(-)) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists, Behav Brain Res, 287, 135, 10.1016/j.bbr.2015.03.053 · DOI
  37. Coates, 2001, Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant α7 and α4β2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes, Br J Pharmacol, 134, 871, 10.1038/sj.bjp.0704315 · DOI · Paper page

Cited by

See all 84

Metadata

Authors
Strasburger, S. E., Bhimani, P. M., Kaabe, J. H., Krysiak, J. T., Nanchanatt, D. L., Nguyen, T. N., Pough, K. A., Prince, T. A., Ramsey, N. S., Savsani, K. H., Scandlen, L., Cavaretta, M. J., & Raffa, R. B.
Venue
Journal of Clinical Pharmacy and Therapeutics
Publisher
Wiley
Published
2017-01-22
Volume
42
Issue
2
Pages
147-154
ISSN
0269-4727 (ISSN-L)
OpenAlex
W2579968803
Cited by
84
References
30
FWCI
6.70
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.